Thanh bên bài viết

PDF
Đã xuất bản: 2022-06-13
Số lượt xem tóm tắt: 90
Số lượt xem PDF: 100
DOI: https://doi.org/10.52852/tcncyh.v154i6.687
Số xuất bản
Tập 154 Số 6 (2022): Tập 154 số 6 E10
Chuyên mục
Các bài báo
Cách trích dẫn
Lien, L. T., Cong, M. T., Le, N. N. Q., Trang, L. H. ., Thach, H. N., Nha, P. V., & Thuy, N. T. D. (2022). 11. Subcutaneous immunoglobulin therapy shortens corticosteroid use in children with dermatomyositis: A case report. Tạp Chí Nghiên cứu Y học, 154(6), 86-92. https://doi.org/10.52852/tcncyh.v154i6.687 (Original work published 11 Tháng Sáu 2022)

11. Subcutaneous immunoglobulin therapy shortens corticosteroid use in children with dermatomyositis: A case report

Luong Thi Lien, Mai Thanh Cong, Nguyen Ngoc Quynh Le, Le Huyen Trang, Hoang Ngoc Thach, Phan Van Nha, Nguyen Thi Dieu Thuy

Nội dung chính của bài viết

Tóm tắt

Dermatomyositis (DM) is a rare autoimmune disease characterized by symmetric proximal muscle weakness and skin rashes. Corticosteroids and methotrexate are mainly prescribed to treat dermatomyositis based on the consensus of experts. Intravenous immunoglobulin is used in severe cases to reduce the dose and duration of corticosteroid therapy, the number of flare-up periods, thereby reducing complications and sequelae. Subcutaneous immunoglobulin has advantages over intravenous immunoglobulin because it can be used at home and maintains stable blood gammaglobulin levels. We report a case of a 2-years old child with early-onset dermatomyositis treated with subcutaneous immunoglobulin. The child’s condition improved, and corticosteroids were discontinued after 18 months of treatment. We prove that subcutaneous immunoglobulin therapy can shorten the duration of corticosteroid therapy in children with dermatomyositis.

Chi tiết bài viết

Từ khóa

Dermatomyositis, juvenile dermatomyositis, subcutaneous immunoglobulin

Tài liệu tham khảo

1. Aussy A, Boyer O, Cordel N. Dermatomyositis and Immune-Mediated Necrotizing Myopathies: A Window on Autoimmunity and Cancer. Front Immunol. 2017; 8:992. Published 2017 Aug 21. doi:10.3389/fimmu.2017.00992.
2. DeWane ME, Waldman R, Lu J. Dermatomyositis: Clinical features and pathogenesis. J Am AcadDermatol. 2020; 82(2):267-281. doi:10.1016/j.jaad.2019.06.1309
3. Lundberg IE, Tjärnlund A, Bottai M, et al. 2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups [published correction appears in Ann Rheum Dis. 2018 Sep; 77(9):e64]. Ann Rheum Dis. 2017; 76(12): 1955-1964. doi:10.1136/annrheumdis-2017-211468.
4. Huber AM, Giannini EH, Bowyer SL, et al. Protocols for the initial treatment of moderately severe juvenile dermatomyositis: results of a Children’s Arthritis and Rheumatology Research Alliance Consensus Conference. Arthritis Care Res (Hoboken). 2010; 62(2): 219-225. doi:10.1002/acr.20071
5. Ruperto N, Pistorio A, Oliveira S, et al. Prednisone versus prednisone plus ciclosporin versus prednisone plus methotrexate in new-onset juvenile dermatomyositis: a randomised trial. Lancet. 2016; 387(10019): 671-678. doi:10.1016/S0140-6736(15)01021-1
6. Stringer E, Bohnsack J, Bowyer SL, et al. Treatment approaches to juvenile dermatomyositis (JDM) across North America: The Childhood Arthritis and Rheumatology Research Alliance (CARRA) JDM Treatment Survey. J Rheumatol. 2010; 37(9): 1953-1961. doi:10.3899/jrheum.090953
7. Cherin P, Herson S, Wechsler B, et al. efficacy of intravenous gammaglobulin therapy in chronic refractory polymyositis and dermatomyositis: an open study with 20 adult patients. Am J Med. 1991; 91(2): 162-168. doi:10.1016/0002-9343(91)90009-m.
8. Cherin P, Belizna C, Cartry O, et al. Long-term subcutaneous immunoglobulin use in inflammatory myopathies: A retrospective review of 19 cases. Autoimmun Rev. 2016; 15(3): 281-286. doi:10.1016/j.autrev.2015.12.003.
9. Abolhassani H, Sadaghiani MS, Aghamohammadi A, Ochs HD, Rezaei N. Home-based subcutaneous immunoglobulin versus hospital-based intravenous immunoglobulin in treatment of primary antibody deficiencies: systematic review and meta analysis. J ClinImmunol. 2012; 32(6): 1180-1192. doi: 10.1007/s10875-012-9720-1
10. Lazarevic D, Pistorio A, Palmisani E, et al. The PRINTO criteria for clinically inactive disease in juvenile dermatomyositis. Ann Rheum Dis. 2013; 72(5): 686-693. doi:10.1136/annrheumdis-2012-201483.
11. Danieli MG, Pettinari L, Moretti R, Logullo F, Gabrielli A. Subcutaneous immunoglobulin in polymyositis and dermatomyositis: a novel application. Autoimmun Rev. 2011; 10(3): 144-149. doi:10.1016/j.autrev.2010.09.004.
12. Gelfand EW. Intravenous immune globulin in autoimmune and inflammatory diseases. N Engl J Med. 2012; 367(21): 2015-2025. doi:10.1056/NEJMra1009433
13. Dalakas MC, Illa I, Dambrosia JM, et al. A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. N Engl J Med. 1993; 329(27): 1993-2000. doi:10.1056/NEJM199312303292704.
14. Choy EH, Isenberg DA. Treatment of dermatomyositis and polymyositis. Rheumatology (Oxford). 2002; 41(1): 7-13. doi:10.1093/rheumatology/41.1.7.
15. Gelardi C, Paolini L, Danieli MG. Subcutaneous immunoglobulin G in idiopathic inflammatory myopathies: therapeutic implications. Isr Med Assoc J. 2014; 16(10): 646-647.